3/21
08:06 am
lvtx
LAVA Therapeutics (NASDAQ: LVTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
LAVA Therapeutics (NASDAQ: LVTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
3/20
07:00 am
lvtx
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
Medium
Report
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
3/5
07:44 am
lvtx
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223) [Yahoo! Finance]
High
Report
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223) [Yahoo! Finance]
3/5
07:30 am
lvtx
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
High
Report
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
1/25
07:12 am
lvtx
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA® [Yahoo! Finance]
High
Report
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA® [Yahoo! Finance]
1/25
07:00 am
lvtx
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
Medium
Report
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®